Please assess the completion status of the following clinical trial:

Trial Title: Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females.~* Age more than 18 and below 80 years.~* Patients with stable CAD planned for elective PCI.~* Thienopyridine naive for at least two weeks before admission.~Exclusion Criteria:~* Pregnant~* Any urgent/emergent coronary angiography procedure that would not allow for genetic testing to be performed before PCI~* Considered at high risk for bleeding~* History of ischemic or hemorrhagic stroke or transient ischemic attack~* . Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with Ticagrelor): ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromycin~* History of ACS within 12 months of screening or need for revascularization~* Any acute or chronic unstable condition.~* Liver disease.~* Have increased bleeding risk, e.g., recent gastrointestinal bleed, uncontrolled high blood pressure, low platelet count.~* History of intolerance or allergy to ticagrelor or clopidogrel~* Patient on dialysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: ACTIVE_COMPARATOR): The primary endpoint is the non-inferiority in platelet reactivity of clopidogrel versus ticagrelor among CYP2C19\*2 or \*3 allele carriers.
- Ticagrelor (Type: EXPERIMENTAL): The primary endpoint is the non-inferiority in platelet reactivity of clopidogrel versus ticagrelor among CYP2C19 CYP2C19\*2 or \*3 allele carriers.

Based on this trial design, predict the completion outcome and termination type (if applicable).